IFCC Interim Guidelines on Molecular Testing of SARS-CoV-2 Infection
The diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection globally has relied extensively on molecular testing, contributing vitally to case identification, isolation, contact tracing, and rationalization of infection control measures during the coronavirus disease 2019 (COVID-19) pandemic. Clinical laboratories have thus needed to verify newly developed molecular tests and increase testing capacity at an unprecedented rate. As the COVID-19 pandemic continues to pose a global health threat, laboratories continue to encounter challenges in the selection, verification, and interpretation of these tests. This document by the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications and target populations, (B) assay selection, (C) assay verification, and (D) test interpretation and limitations for molecular testing of SARS-CoV-2 infection. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide and highlight the continued importance of laboratory medicine in our collective pandemic response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 58(2020), 12 vom: 07. Okt., Seite 1993-2000 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bohn, Mary Kathryn [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 30.11.2020 Date Revised 12.02.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2020-1412 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31597169X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31597169X | ||
| 003 | DE-627 | ||
| 005 | 20231225160053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2020-1412 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM31597169X | ||
| 035 | |a (NLM)33027042 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bohn, Mary Kathryn |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IFCC Interim Guidelines on Molecular Testing of SARS-CoV-2 Infection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2020 | ||
| 500 | |a Date Revised 12.02.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection globally has relied extensively on molecular testing, contributing vitally to case identification, isolation, contact tracing, and rationalization of infection control measures during the coronavirus disease 2019 (COVID-19) pandemic. Clinical laboratories have thus needed to verify newly developed molecular tests and increase testing capacity at an unprecedented rate. As the COVID-19 pandemic continues to pose a global health threat, laboratories continue to encounter challenges in the selection, verification, and interpretation of these tests. This document by the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications and target populations, (B) assay selection, (C) assay verification, and (D) test interpretation and limitations for molecular testing of SARS-CoV-2 infection. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide and highlight the continued importance of laboratory medicine in our collective pandemic response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a molecular testing | |
| 650 | 4 | |a virology | |
| 700 | 1 | |a Mancini, Nicasio |e verfasserin |4 aut | |
| 700 | 1 | |a Loh, Tze Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Cheng-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Grimmler, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Gramegna, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Yuen, Kwok-Yung |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Koch, David |e verfasserin |4 aut | |
| 700 | 1 | |a Sethi, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Rawlinson, William D |e verfasserin |4 aut | |
| 700 | 1 | |a Clementi, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Erasmus, Rajiv |e verfasserin |4 aut | |
| 700 | 1 | |a Leportier, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Gye Cheol |e verfasserin |4 aut | |
| 700 | 1 | |a Menezes, María Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Patru, Maria-Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Krishna |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Najjar, Osama |e verfasserin |4 aut | |
| 700 | 1 | |a Horvath, Andrea R |e verfasserin |4 aut | |
| 700 | 1 | |a Adeli, Khosrow |e verfasserin |4 aut | |
| 700 | 1 | |a Lippi, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 58(2020), 12 vom: 07. Okt., Seite 1993-2000 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2020 |g number:12 |g day:07 |g month:10 |g pages:1993-2000 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2020-1412 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2020 |e 12 |b 07 |c 10 |h 1993-2000 | ||